MARKET OUTLOOK
After a detailed analysis, Triton Market Research has concluded that the global hyperphosphatemia drugs market is expected to display an upward trend and is estimated to grow at a CAGR of 16.61% in terms of revenue over the forecast period of 2019 to 2027.
Hyperphosphatemia normally affects individuals in the late stages of kidney disease. Diabetes and hypertension are major causes of renal dysfunction. A rise in the prevalence of these conditions increases the number of people with CKD that are on dialysis. Phosphate binders are used to treat hyperphosphatemia, but the drugs have some adverse effects. This leads to the increased need for effective treatment options, compelling vendors to extensively invest in the R&D of new drugs. The prevalence of chronic kidney diseases in the elderly population is very high, with more than 35% of patients over 70 years of age suffering from stage 3 chronic kidney disease. This has increased the use of phosphate binding drugs in the market. Phosphorus is essential for normal physiological functions such as bone construction, nerve function, and muscle contraction. Most of the phosphorus is stored in the bones and different tissues of the body.
The rapidly growing chronic disorders, rising public awareness and the growth in the elderly population are the key driving factors of the hyperphosphatemia drugs market. Factors such as the strict FDA regulations and the side-effects caused due to the consumption of hyperphosphatemia drugs are obstructing the growth of this industry. The growing aging populace is a key opportunity that can be leveraged by this market in order to supplement further growth. However, the option of choosing alternative dialysis techniques as well as non-adherence to treatment regimes and limited access to drugs are the challenges being faced by the hyperphosphatemia drugs market at this moment.
REGIONAL OUTLOOK
The main regions included in the hyperphosphatemia drugs market are North America, Europe, Latin America, APAC and the Middle East and Africa.
North America is the clear leader in the global hyperphosphatemia drugs market in terms of revenue. The hyperphosphatemia drugs market in North America is driven by the increasing rate of a number of chronic kidney disorders and increasing prevalence of diabetes & osteoporosis across the region. Asia-Pacific is the fastest-growing region in the hyperphosphatemia drugs market. China is expected to be the largest healthcare drugs and equipment market in Asia-Pacific region both by revenue and size. The rapidly expanding healthcare infrastructure throughout the country, driven solid growth efforts being undertaken by the country’s central government is projected to fuel demand for hyperphosphatemia drugs across China.
COMPETITIVE OUTLOOK
Sanofi, Pfizer, Inc., Zeria Pharmaceutical, Bio-Tech Pharmacal, Roche Diagnostics Corporation, Ultragenyx Pharmaceutical, Inc., Fresenius Medical Care, Shire, Keryx Biopharmaceuticals, Inc., Royal DSM N.V., Fermenta Biotech, Ltd., Cipla, Bruno Farmaceutici S.p.A., Johnson and Johnson, Sun Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals are the companies leading the hyperphosphatemia drugs market.
Bruno Farmaceutici S.p.A. is the manufacturer and marketer of the pharmaceutical products. The company is dedicated to improving health by deploying the production and supply of the drugs and provides quality, efficacy and safety. The company’s product, Diosmix, is a disposable device which comes in a sachet and is in the form of a powder for extemporaneous oral suspension. It is for the treatment of chronic diarrheas and gastrointestinal diseases’ painful symptoms. Orexigen Therapeutics Ireland has announced an agreement with Bruno Farmaceutici S.p.A. for the commercialization and distribution of Mysimba.